Design of Aminobenzothiazole Inhibitors of Rho Kinases 1 and 2 by Using Protein Kinase A as a Structure Surrogate.Judge, R.A., Vasudevan, A., Scott, V.E., Simler, G.H., Pratt, S.D., Namovic, M.T., Putman, C.B., Aguirre, A., Stoll, V.S., Mamo, M., Swann, S.I., Cassar, S.C., Faltynek, C.R., Kage, K.L., Boyce-Rustay, J.M., Hobson, A.D.
(2018) Chembiochem 19: 613-621
- PubMed: 29314498
- DOI: https://doi.org/10.1002/cbic.201700547
- Primary Citation of Related Structures:
5VHB, 5VI9, 5VIB
- PubMed Abstract:
We describe the design, synthesis, and structure-activity relationships (SARs) of a series of 2-aminobenzothiazole inhibitors of Rho kinases (ROCKs) 1 and 2, which were optimized to low nanomolar potencies by use of protein kinase A (PKA) as a structure surrogate to guide compound design. A subset of these molecules also showed robust activity in a cell-based myosin phosphatase assay and in a mechanical hyperalgesia in vivo pain model.
Current address: Genentech, 1 DNA Way, South San Francisco, CA, 94080, USA.